Tumor microenvironment-simulated organoids for personalized therapy prediction in head and neck squamous cell carcinoma

Jianguo Gan Wan-Rong Meng Fan Yang C. Cao Jia-Lu He Ling Li Xiao-Yi Wang Xiao-Dong Feng Gui-Quan Zhu

Aug 2026 · Oncogene · Vol 45, pp. 4065 - 4076 · 0 citations · 40 references

Medicine

TL;DR

Collectively, MS-PDOs serve as a robust platform for modeling the tumor microenvironment and predicting therapeutic responses, supporting precision medicine-guided clinical decision-making and offering personalized treatment strategies for HNSCC patients.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Oct 2026

Prostate Cancer Patient-Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)-Based Personalized Therapy.

Patient-derived tumor organoids (PDOs) closely preserve the cellular heterogeneity, histopathology, and molecular features of the original tumors, making them powerful preclinical models. Antisense oligonucleotides (ASOs) are an emerging class of precision medicines that modulate gene expression at the RNA level with h...

Thi Thom Tran, Thi Thuc Uyen Phan, M. Baboudjian et al. · Advanced Healthcare Material... · 0 citations

Review Open access Sep 2026

Patient-derived tumor organoid co-culture systems as translational platforms for cancer immunotherapy and precision oncology

The tumor microenvironment (TME) is a dynamic and immunosuppressive niche that critically governs cancer progression, immune evasion, and therapeutic resistance. Accurately modeling tumor–immune interactions in vitro is therefore essential for advancing our understanding of cancer biology and accelerating the developme...

Mohamed Gadelkarim, Ahmed Elsayed, Tasneem Abaza et al. · Clinical Cancer Bulletin · 0 citations

Aug 2026

Integrating Patient-derived Organoid and Patient-derived Xenograft Models to Guide Precision Chemotherapy for Gastric Cancer

Background/Aim: The present study aimed to establish patient-derived organoid (PDO) and patient-derived xenograft (PDX) models from clinical gastric cancer (GC) tissue samples and analyze their drug sensitivity data to evaluate their translational value in GC research. The present study investigated the integrated cons...

He-Zhong Yan, Xing He, Xilu Hou et al. · Anticancer Research · 0 citations

Review Open access Sep 2026

Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology

Prostate cancer ranks among the most prevalent male malignancies worldwide, with castration-resistant prostate cancer (CRPC) and drug resistance representing major clinical challenges. Conventional preclinical models fail to faithfully recapitulate tumor heterogeneity and the tumor microenvironment (TME). Patient-deriv...

Jing-Zhen Zhu, Sheng Wang, Fu-Rong Du et al. · Frontiers in Oncology · 0 citations

Open access Sep 2026

Patient-derived organoids enable ex vivo drug-response profiling for precision medicine in bladder cancer

Patient-derived organoids (PDOs) represent a promising precision medicine approach for replicating primary tumor characteristics and facilitating drug testing across various cancers, although clinical evidence in bladder cancer remains limited. This study evaluates the impact of incorporating PDOs into clinical pract...

Si-Jia Li, Feng Qiu, Fang-Yue Zheng et al. · npj Precision Oncology · 0 citations

Sep 2026

A Paired Tumor Organoid-Stroma Biobank Reveals PLAU⁺ Fibroblasts as Drivers of Chemoresistance in Lung Adenocarcinoma.

Chemotherapy is a standard treatment for lung adenocarcinoma (LUAD), yet the efficacy is often limited, highlighting the need to elucidate and the underlying mechanisms of chemoresistance. Given the important role of the tumor microenvironment in LUAD progression, we established a biobank of patient-derived LUAD organo...

Si-Qi Li, Ze Zhang, Quan-Kun Lv et al. · Cancer Research · 0 citations